— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year.
— Net loss was $21.5 million compared to $20.4 million last year.
— Research and development expenses were $15.5 million versus $16.9 million for 2018.
— Cash and cash equivalents as of December 31, 2019, totaled $22.7 million, compared to $17 million as of December 31, 2018.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
